In its first proof-of-concept application, MiChip can simultaneously detect three serum protein biomarkers: carcinoembryonic antigen (CEA), AFP, and prostate-specific antigen (PSA), all of which are commonly used in clinical tests for colorectal, hepatocellular, and prostate cancers, respectively. This evidence concerns the gene AFP and prostate cancer.